Synthesis and Characterisation of a Doxorubicin-CNGRC Peptide Conjugate that Targets Tumour Vasculature

Fabrice Anizon; F. Thomas Boyle; Julie Fisher; Philip J. Kocienski

doi:10.1055/s-2002-35995

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000084.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synthesis 2002(18): 2733-2736
DOI: 10.1055/s-2002-35995

PAPER

Synthesis and Characterisation of a Doxorubicin-CNGRC Peptide Conjugate that Targets Tumour Vasculature [1]

Fabrice Anizon^a,, F. Thomas Boyle^b, Julie Fisher^a, Philip J. Kocienski*^a
^a Department of Chemistry, Leeds University, Leeds, LS2 9JT, UK
^b AstraZeneca Pharmaceuticals, Alderly Edge, Mereside, Macclesfield, Cheshire, SK10 4TG, UK
e-Mail: p.kocienski@chemistry.leeds.ac.uk;

Further Information

Publication History

Received 12 September 2002
Publication Date:
06 December 2002 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

A conjugate between the cyclic peptide CNGRC and doxorubcin, previously reported as a ligand of aminopeptidase N (CD13), has been synthesised and characterised.

Key words

solid-phase synthesis - CNGRC - peptides - doxorubicin - angiogenesis - macrocycles - anti-tumour agents

1

Abbreviations: Acm, acetamidomethyl; DIPEA, N,N-diisopropylethylamine; Fmoc, 9-fluorenylmethoxycarbonyl; HOBt, 1-hydroxybenzotriazole; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; PyBOP, benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate.

References

3 Risau W. Nature (London) 1997, 386: 671

Crossref Google Scholar
4 Zetter BR. Ann. Rev. Med. 1998, 49: 407

Crossref Google Scholar
5 Ruoslahti E. Ann. Rev. Cell Dev. Biol. 1996, 12: 697

Crossref Google Scholar
6 Pasqualini R. Koivunen E. Ruoslahti E. Nature Biotechnol. 1997, 15: 542

Crossref Google Scholar
7 Haubner R. Finsinger D. Kessler H. Angew. Chem., Int. Ed. Engl. 1997, 36: 1375

Google Scholar
8 Arap W. Pasqualini R. Ruoslahti E. Science 1998, 279: 377

Crossref Google Scholar
9 Koivunen E. Gay DA. Ruoslahti E. J. Biol. Chem. 1993, 268: 20205

Google Scholar
10 Koivunen E. Wang BC. Ruoslahti E. J. Cell Biol. 1994, 124: 373

Crossref Google Scholar
11 Healy JM. Murayama O. Maeda T. Yoshino K. Sekiguchi K. Kikuchi M. Biochemistry 1995, 34: 3948

Crossref Google Scholar
12 Pasqualini R. Koivunen E. Kain R. Lahdenranta J. Sakamoto M. Stryhn A. Ashmun RA. Shapiro LH. Arap W. Ruoslahti E. Cancer Res. 2000, 60: 722

Google Scholar
13 Ellerby HM. Arap W. Ellerby LM. Kain R. Andrusiak R. DelRio G. Krajewski S. Lombardo CR. Rao R. Ruoslahti E. Bredesen DE. Pasqualini R. Nature Medicine 1999, 5: 1032

Crossref Google Scholar
14 Pons M. Albericio F. Royo M. Giralt E. Synlett 2000, 172

Article in Thieme Connect Google Scholar
15 Veber DF. Milkowski JD. Varga SL. Denkewalter RG. Hirschmann R. J. Am. Chem. Soc. 1972, 94: 5456

Crossref Google Scholar
16 Carpino LA. Shroff HN. Triolo SA. Mansour EMA. Wenschuh H. Albericio F. Tetrahedron Lett. 1993, 34: 7829

Crossref Google Scholar

1

Abbreviations: Acm, acetamidomethyl; DIPEA, N,N-diisopropylethylamine; Fmoc, 9-fluorenylmethoxycarbonyl; HOBt, 1-hydroxybenzotriazole; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; PyBOP, benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate.

2

Present address: Synthèse et Etude de Systèmes à Intéret Biologique, Université Blaise Pascal, UMR 6504, 63177 Aubière, France.